Table 2.
Results from the multivariate analysis. HR, 95% CI and p-value are given for each factor.
| Factor | Mortality | TRM | Relapse | Acute GVHD II-IV | Chronic GVHD | GRFS | Time to ANC >0.5 × 109/L | |
|---|---|---|---|---|---|---|---|---|
| Patient age p value |
Cont. | 1.02, 1.01–1.04, p=0.02 | 1.04, 1.01–1.07, p=0.015 | 0.98, 0.96–1.01, p=0.16 | 0.99, 0.97–1.02, p=0.77 | 1.00, 0.98–1.02, p=0.92 | 0.99, 0.98–1.01, p=0.74 | – |
| F to M p value |
Yes | 1.66, 1.09–2.52, p=0.02 | 1.59, 0.90–2.77, 0.11 | 1.19, 0.69–2.05, 0.53 | 1.00, 0.61–1.65, 0.99 | 2.05, 1.34–3.14, <0.001 | 1.40, 0.98–2.02, 0.07 | 1.36, 0.61–3.03, 0.44 |
| Acute leukemia | Reference | Reference | ||||||
| MDS/MPN | 1.69, 0.89–3.21, 0.11 | 0.90, 0.66–1.22, 0.49 | 0.84, 0.55–1.26, 0.40 | 0.90, 0.62–1.28, 0.55 | 0.96, 0.72–1.28, 0.79 | 1.83, 1.07–3.13, 0.03 | 1.20, 0.74–1.97, 0.46 | |
| Diagnosis p value | Lymphoma | 1.12, 0.45–2.80, 0.81 | 0.71, 0.30–1.64, 0.42 | |||||
| Other | 1.32, 0.57–3.04, 0.52 | 1.02, 0.45–2.27, 0.97 | ||||||
| Disease stage p value |
Early (CR1/CP1) | 1.20, 0.71–2.03, 0.49 | 1.03, 0.53–2.01, 0.93 | 0.91, 0.44–1.88, 0.80 | 0.81, 0.46–1.44, 0.48 | 0.94, 0.57–1.55, 0.82 | 1.14, 0.74–1.75, 0.56 | 1.07, 0.47–2.64, 0.87 |
| GVHD prophylaxis p value |
CsA+MTX | 0.83, 0.39–1.78, 0.63 | 0.71, 0.33–1.53, 0.39 | 1.12, 0.46–2.70, 0.81 | 1.22, 0.52–2.83, 0.65 | 0.99, 0.54–1.85, 0.99 | 0.79, 0.38–1.61, 0.51 | 13.9, 3.81–50.7, <0.001 |
| Conditioning p value |
MAC | 1.58, 0.92–2.71, 0.10 | 2.08, 1.01–4.26, <0.05 | 0.92, 0.43–1.96, 0.82 | 0.80, 0.44–1.46, 0.47 | 1.23, 0.72–2.11, 0.45 | 1.09, 0.69–1.72, 0.72 | 2.13, 0.89–5.09, 0.09 |
| CD 34 dose p value |
6–7 × 106/kg | 0.43, 0.25–0.77, 0.004 | 0.41, 0.18–0.92, 0.03 | – | – | 0.65, 0.42–0.99, 0.04 | – | |
| <5 × 106/kg | – | – | 1.96, 1.12–3.42, 0.02 | – | 0.57, 0.36–0.90, 0.016 | – | 2.46, 1.15–5.27, 0.02 | |
| >6.5 × 106/kg | – | – | – | 0.50, 0.27–0.92, 0.025 | – | |||
| Donor age | Cont. | – | – | – | – | – | – | 1.04, 1.01–1.07, 0.01 |
HR: hazards ratio, CI: confidence interval, F to M: female donor to male recipient, GVHD: graft-versus-host disease, MDS/MPN: myelodysplastic syndrome/myeloproliferative neoplasm, CR1/CP1: complete remission 1/chronic phase 1, CsA + MTX: cyclosporine A + methotrexate, MAC: myeloablative conditioning, OS: overall survival, TRM: transplant-related mortality, GRFS: graft-versus-host disease and relapse-free survival, RFS: relapse-free survival, ANC: absolute neutrophil count.